Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of intravenous TAK-954 in critically ill patients with enteral feeding intolerance
2017-003206-41Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of felcisetrag in enteral feeding intolerance (EFI) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Average daily protein adequacy over first 5 days. Started Mar 2018; status: terminated.
02
Drugs
felcisetrag
03
Conditions
enteral feeding intolerance (EFI)
Beyond the preview
Go deeper on 2017-003206-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003206-41.